论文部分内容阅读
人类某些癌症及部分急性白血病(AML)的多药耐受性是成功化疗的主要障碍。研究证实MDR1是AML耐药机理中最有代表性的基因,且与预后差有关。但是,有些体外药物耐受研究并未观察到MDR1表达。提示另一些蛋白,如最近认识的多药耐受相关蛋白(MRP)或肺耐受蛋白(LRP)与MDR表达有关由于测定LRP的几种方法常产生不相同的结果,以至AML的LRP表达在临床药物耐受中的作用是有争议的。作者用反转录聚合酶链式反应(RT-PCR)、免疫细胞化学法(ICC)和流式细胞仪(FC)检测了10种细胞株和47例AML患者新鲜及冻存细胞LRP的表达水平,对结果进行比较。研究选用10种对LRP有
Multidrug resistance in certain human cancers and some acute leukemias (AML) is a major obstacle to successful chemotherapy. Studies have confirmed that MDR1 is the most representative gene in the AML resistance mechanism and is associated with poor prognosis. However, some in vitro drug tolerance studies did not observe MDR1 expression. This suggests that other proteins, such as the recently recognized multi-drug tolerance-associated protein (MRP) or lung resistance protein (LRP), are associated with MDR expression. Several methods for measuring LRP often produce different results, resulting in the expression of LRP in AML. The role of clinical drug resistance is controversial. The authors used reverse transcription polymerase chain reaction (RT-PCR), immunocytochemistry (ICC) and flow cytometry (FC) to detect the expression of LRP in fresh and frozen cells from 10 cell lines and 47 AML patients. Level, compare results. Study selected 10 types of LRP